The U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with ...

Vyalev, also known as Produodopa, has been approved in 35 countries, with more than 4200 patients having started treatment.

▎药明康德内容团队编辑艾伯维（AbbVie）今天宣布，美国FDA已批准Vyalev（foscarbidopa和foslevodopa）上市，用于治疗晚期帕金森病（PD）成人患者的运动能力波动。新闻稿指出，这是FDA批准的首款基于左旋多巴的皮下24小时 ...

The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced ...

AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system ...

伊利诺伊州北芝加哥 - 艾伯维公司(NYSE: ABBV)今天宣布,美国食品和药物管理局(FDA)批准了VYALEV™,这是首个针对晚期帕金森氏症成年患者的24小时持续皮下输液疗法。这种新疗法旨在管理运动波动,这是帕金森氏症的一个常见挑战,并允许全天候个性化给药。 该批准基于一项关键的三期研究,该研究表明,与口服卡比多巴/左旋多巴相比,接受VYALEV治疗的患者在运动症状控制方面表现更好,如无烦人 ...

The first levodopa-based treatment for motor fluctuations in people with advanced Parkinson's disease, VYALEVa subcutaneous ...

The US Food and Drug Administration (FDA) has approved AbbVie's VYALEV (foscarbidopa and foslevodopa) to treat motor ...

The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...

The FDA on Thursday approved an injectable drug that eased Parkinson's disease symptoms and improved motor fluctuations in ...

AbbVie announced that the FDA has approved Vyalev as the first and only subcutaneous 24-hour infusion of levodopa-based ...

Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.